1. Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06
- Author
-
Anna Michelato, Fabio Ciceri, Dario Ferrero, Lorella De Paoli, Renato Bassan, Chiara Caprioli, Paolo Corradini, Silvia Salmoiraghi, Brunangelo Falini, Chiara Cattaneo, Giacomo Gianfaldoni, Agostino Cortelezzi, Federica Delaini, Alessandro Rambaldi, Francesco Mannelli, Leonardo Campiotti, Anna Maria Scattolin, Pamela Zanghì, Erika Borlenghi, Federico Lussana, Massimo Bernardi, Ksenija Buklijas, Daniele Mattei, Elena Oldani, Monica Tajana, Tamara Intermesoli, Roberta Cavagna, Anna De Grassi, Irene Cavattoni, Ernesta Audisio, Elisabetta Terruzzi, Orietta Spinelli, Lara Elidi, Elisabetta Todisco, Chiara Pavoni, Caprioli, C, Lussana, F, Salmoiraghi, S, Cavagna, R, Buklijas, K, Elidi, L, Zanghi', P, Michelato, A, Delaini, F, Oldani, E, Intermesoli, T, Grassi, A, Gianfaldoni, G, Mannelli, F, Ferrero, D, Audisio, E, Terruzzi, E, De Paoli, L, Cattaneo, C, Borlenghi, E, Cavattoni, I, Tajana, M, Scattolin, A, Mattei, D, Corradini, P, Campiotti, L, Ciceri, F, Bernardi, M, Todisco, E, Cortelezzi, A, Falini, B, Pavoni, C, Bassan, R, Spinelli, O, Rambaldi, A, Caprioli, Chiara, Lussana, Federico, Salmoiraghi, Silvia, Cavagna, Roberta, Buklijas, Ksenija, Elidi, Lara, Zanghi', Pamela, Michelato, Anna, Delaini, Federica, Oldani, Elena, Intermesoli, Tamara, Grassi, Anna, Gianfaldoni, Giacomo, Mannelli, Francesco, Ferrero, Dario, Audisio, Ernesta, Terruzzi, Elisabetta, De Paoli, Lorella, Cattaneo, Chiara, Borlenghi, Erika, Cavattoni, Irene, Tajana, Monica, Scattolin, Anna Maria, Mattei, Daniele, Corradini, Paolo, Campiotti, Leonardo, Ciceri, Fabio, Bernardi, Massimo, Todisco, Elisabetta, Cortelezzi, Agostino, Falini, Brunangelo, Pavoni, Chiara, Bassan, Renato, Spinelli, Orietta, and Rambaldi, Alessandro
- Subjects
Acute Myeloid Leukemia ,Oncology ,medicine.medical_specialty ,Myeloid ,Cytogenetics and Molecular Genetics ,Myelodysplastic Syndromes ,Article ,law.invention ,Cytogenetics and Molecular Genetic ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Secondary Acute Myeloid Leukemia ,Clinical significance ,Prospective Studies ,Prospective cohort study ,neoplasms ,Aged ,Myeloproliferative Disorders ,business.industry ,Myelodysplastic syndromes ,Myeloid leukemia ,Hematology ,Prognosis ,medicine.disease ,Chromatin ,Leukemia, Myeloid, Acute ,Leukemia ,medicine.anatomical_structure ,Spliceosomes ,business ,030215 immunology - Abstract
Secondary acute myeloid leukemia (sAML) after myelodysplastic or myeloproliferative disorders is a high-risk category currently identified by clinical history or specific morphological and cytogenetic abnormalities. However, in the absence of these features, uncertainties remain to identify the secondary nature of some cases otherwise defined as de novo AML. To test whether a chromatin-spliceosome (CS) mutational signature might better inform the definition of the de novo AML group, we analyzed a prospective cohort of 413 newly diagnosed AML patients enrolled into a randomized clinical trial (NILG AML 02/06) and provided with accurate cytogenetic and molecular characterization. Among clinically defined de novo AML, 17.6% carried CS mutations (CS-AML) and showed clinical characteristics closer to sAML (older age, lower white blood cell counts and higher rate of multilineage dysplasia). Outcomes in this group were adverse, more similar to those of sAML as compared to de novo AML (overall survival, 30% in CS-AML and 17% in sAML vs 61% in de novo AML, P
- Published
- 2020
- Full Text
- View/download PDF